Pharma Pulse 8/27/24: Inside a Love-Hate Relationship With ChatGPT, Virtual Care's Role in Behavioral Health & more

Targeted Pre-Launch Scientific Outreach

Dan Rizzo, global head of business consulting at Veeva, spoke with Pharmaceutical Executive about his company’s latest findings about how life sciences companies are utilizing targeted pre-launch scientific outreach to improve uptake of novel treatments.

Virtual Care's Role in Behavioral Health — Opportunities and Risks Highlighted Based on Recent Data

Virtual care offers a significant opportunity to bridge the gap between supply and demand in behavioral health services. However, there are risks associated with the lack of integration between virtual care and traditional healthcare systems, particularly in medication management.

Inside Universities’ Love-Hate Relationship With ChatGPT

OpenAI continues to expand some of its educational offerings, while holding others—including a tool that could be used to detect cheating—back.

Reliance Rx Partners with Waltz Health to Lower Costs of Specialty Medications

Waltz Health, a digital health company developing smarter, technology-enabled ways to price, distribute and prescribe medications, and specialty pharmacy leader Reliance Rx announced a partnership to lower the cost of prescription specialty drugs. Reliance Rx joins Waltz Health’s Waltz Connect program as an in-network option for all specialty medications.

Dan Rizzo on LinkedIn

It was great to sit down with Pharmaceutical Executive to share the latest #VeevaPulse findings. Now that we understand more about pre-launch investment in scientific outreach, we can quantify the impact of targeted #medicalaffairs strategies on treatment adoption. Plus, we also found that with early-career experts more open to digital, they are four times more likely to start patients on a new treatment.

Check out the piece (https://lnkd.in/gCVu83Qj). Thank you Pharmaceutical Executive for having me.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs